RSRodolfo Daniel de Almeida Soares

Rodolfo Daniel de Almeida Soares

*This is an algorithmically generated author record based on publicly available information.

Rodolfo Daniel de Almeida Soares has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hypoplastic Myelodysplastic Syndrome: A Latin American Multicenter Analysis

    by Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Maria Cristina Martins de Almeida Macedo, Vaneuza Araújo Moreira Funke, Anderson João Simioni, Neysimélia Costa Villela, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Paz, Mariana Stevenazzi, et al.

  • Open Access

    Hematopoietic cell transplantation for myelodysplastic syndromes

    by Fernando Barroso Barroso, Yhasmine Delles Oliveira Garcia, Karine Sampaio Nunes Barroso, Roberto Luiz da Silva, Lívia Andrade Gurgel, João Paulo de Vasconcelos Leitão, Beatriz Stela Gomes de Souza Pitombeira, Rodolfo Daniel de Almeida Soares, Gustavo Bettarello

    For patients with myelodysplastic syndromes (MDS), allogeneic hematopoietic cell transplantation (HCT) is considered the only treatment with curative potential. However, its use is restricted to a selected group of patients, and transplant outcomes are influenced by a complex interaction of disease related characteristics, patient-specific factors, and the HCT procedure. Since the publication of the previous Brazilian consensus, important advances have been made in the classification and risk stratification of MDS. In 2022, two new classification systems have been updated: the World Health Organization classification and the International Consensus Classification. In addition, the incorporation of molecular information through the Molecular International Prognostic Scoring System has further refined prognostic assessment and therapeutic decision making in patients with MDS. This article updates the Brazilian consensus published in 2021 for Brazilian Society of Cellular Therapy and Bone Marrow Transplantation, incorporating recent developments in the management of patients undergoing HCT. It aims to guide hematologists in transplant indication.

  • Open Access

    Current activity trends and outcomes of hematopoietic cell transplantation: A 2026 report from the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the CIBMTR & SBTMO

    by Anderson João Simione, Cinthya Correa da Silva, Afonso Celso Vigorito, Antonio Vaz Macedo, Heliz Regina Alves das Neves, Vanessa Aparecida Do Nascimento Varjão, Monique Ammi, Flavia Ferreira da Da Costa, Adriana Mendes de Quadros Cavilha, Alayne Magalhães T.D. Yamada, et al.

    The development of the Brazilian Registry of Hematopoietic Cell Transplantation (Registro Brasileiro de Transplantes de Células Hematopoieticas), in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR), continues to provide a comprehensive assessment of hematopoietic cell transplantation (HCT) activity and outcomes in Brazil. In this study, we report an updated analysis of national transplant activity. Brazilian transplant centers report their data to the CIBMTR using the FormsNet3 platform, and data are returned to the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea) through the Data Back to Centers (DBtC) tool. Data from patients who underwent HCT from 2015 to 2025 in Brazilian centers were extracted from the CIBMTR. Descriptive analyses were performed using patient-, disease-, and transplant-related variables, and overall survival was estimated using the Kaplan–Meier method. A total of 15,586 HCTs were included (7,507 autologous and 8,079 allogeneic). For survival analyses, 9,150 patients who underwent a first HCT from 2015 to 2023 were analyzed, with a median follow-up of 35 months. The number of reporting centers increased over time, reaching 51 centers during the study period. Acute leukemias remained the most common indication for allogeneic HCT, while multiple myeloma and lymphomas predominated in autologous HCT. In recent years, mismatched related donors have accounted for the largest proportion of allogeneic transplants. Bone marrow was the main graft source in pediatric patients, whereas peripheral blood predominated in adults. Infections were the most frequent cause of death within the first 100 days after HCT, while primary disease was the leading cause beyond 100 days. Survival patterns varied according to disease characteristics and transplantrelated factors, with lower survival estimates observed in patients transplanted with advanced disease stages. Comparisons with the United States Summary Slides suggest both similarities and differences in transplant activity and outcomes, which should be interpreted with caution given variations in data structure, patient characteristics, and risk stratification.


  • Open Access

    Hematopoietic cell transplantation outcomes in public centers in Brazil: analysis of the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy, 2012–2024

    by Anderson João Simione, Cinthya Corrêa da Silva, Nelson Hamerschlak, Afonso Vigorito, Heliz Regina Alves das Neves, Adriana Seber, Carmem Maria Sales Bonfim Bonfim, Vergilio Antonio Rensi Colturato, Samir Kanaan Nabhan, Vanderson Geraldo Rocha, et al.

    This study provides a national overview of hematopoietic cell transplantation (HCT) outcomes in the Brazil’s public healthcare network, using data consolidated in the Brazilian Registry of Hematopoietic Cell Transplantation and Cellular Therapy (RBTCH-TC). A total of 5,923 first HCTs performed between 2012 and 2024 across 19 public centers were analyzed. Median follow-up among survivors reached 24.5 months, reflecting recent improvements in follow-up completeness and data reliability within the registry. Overall survival, relapse, and non-relapse mortality (NRM) rates were generally consistent with international benchmarks, despite the resource limitations characteristic of a publicly funded system. NRM was concentrated in the first year after allogeneic HCT, whereas relapse remained the predominant cause of late mortality across both autologous and allogeneic procedures. Acute graft versus-host disease (GVHD) was more frequent among recipients of mismatched related and unrelated donors, while chronic GVHD occurred more often in matched related donor transplants. These findings highlight the complexity of transplant care in the public setting and underscore the importance of standardized data collection, integration across centers, and long-term surveillance to support continuous quality improvement. Strengthening national collaborative initiatives such as the RBTCH-TC remains essential for guiding evidence-based strategies and improving patient outcomes throughout Brazil’s public transplant network.


  • Regional Disparities and Socioeconomic Factors Affecting Outcomes of Hematopoietic Cell Transplantation in Brazil: Insights From the Brazilian Bone Marrow Transplant Map

    by Giancarlo Fatobene, Carmen Vergueiro, Anderson João Simione, Lívia Mariano, Vergílio Colturato, José Ulysses Amigo Filho, Rodolfo Froes Calixto, João Vitor Piccolo Feliciano, Jayr Schmidt Filho, Afonso Celso Vigorito, et al.

  • Open Access

    Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry

    by Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Vaneuza Araújo Moreira Funke, Anderson João, Nelson Hamerschlak, Neysimélia Costa Villela, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, Rodolfo Daniel de Almeida Soares, Alessandra Aparecida Paz, et al.

    This retrospective multicenter study aimed to compare outcomes and evaluate risks associated with allogeneic hematopoietic cell transplantation (allo‐HCT) in myelodysplastic syndrome patients aged ≥ 65 versus < 65 years in Latin America, across 38 transplant centers (1988–2023). Of the 441 patients, 70 (16%) were ≥ 65 years (median age 68 ± 3.7). At 5 years, overall survival (OS) was 49.3% in patients ≥ 65 vs. 56.7% in those < 65 (p = 0.49), and progression‐free survival (PFS) was 48.4% vs. 56.2% (p = 0.40). The cumulative incidence of relapse was 13.6%, and non‐relapse mortality (NRM) 33.8%. After propensity score matching, no significant differences were observed between the age groups in OS (HR = 1.16; 95% CI: 0.76–1.77; p = 0.488), NRM (HR = 1.03; 95% CI: 0.64–1.67; p = 0.90) or PFS (HR = 1.20; 95% CI: 0.779–1.83; p = 0.40). PFS in patients ≥ 65 years was associated with high‐risk IPSS‐R stratification (p = 0.0056). The age group ≥ 65 years conferred higher risk of relapse compared to patients aged < 65 years (HR = 2.77; 95% CI: 1.07–7.15; p = 0.035). In patients ≥ 65 years, prevalence risk was associated to male sex, reduced‐intensity conditioning, mobilized blood cells, and prior treatment, while in those < 65 years, to complications and chronic GVHD (p < 0.05). HCT is feasible in elderly patients. However, age may influence disease progression in very high‐risk elderly patients and risk of relapse after transplantation.


  • Open Access

    Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators

    by Anderson João Simione, Cinthya Silva, Afonso Vigorito, Antonio Macedo, Heliz Neves, Paula Sabaini, Monique Ammi, Flavia Costa, Adriana Cavilha, Rosana Concilio, et al.

    Systematic evaluation of hematopoietic cell transplantation (HCT) outcomes is essential to improve clinical practice and meet international quality standards. In Brazil, the partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR) has advanced national data reporting and benchmarking through the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR). This study reports outcomes from 11,210 first HCTs (5,984 allogeneic; 5,226 autologous) performed between 2012 and 2023 across 44 Brazilian centers. Median recipient age was 29 years for allogeneic and 53 years for autologous transplants. Acute leukemias predominated among allogeneic cases, while multiple myeloma was the most common indication for autologous HCT. Two-year overall survival was 82.0% for autologous and 59.8% for allogeneic transplants, with variation by donor type (matched related 61.8%, mismatched related 54.0%, unrelated 63.3%). Two-year non-relapse mortality was 8.0% and 21.6% for autologous and allogeneic transplants, respectively. The cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) at two years was 29.9%, with chronic GVHD incidence of 29.5%. Two-year relapse incidence was 24.1% for allogeneic and 25.8% for autologous HCT. Despite challenges within the Brazilian healthcare system, these outcomes align with international registry data. Adequate data completeness supports the robustness of these findings. Our results highlight the quality of Brazilian transplant programs and underscore the value of standardized outcome monitoring to foster continuous improvement. Strengthening center participation, follow-up, and data management remains critical to maintaining registry quality and enhancing patient care.


  • Open Access

    CURRENT USE AND OUTCOMES OF HEMATOPOIETIC CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2025

    by Anderson João Simione, Cinthya Silva, Afonso Vigorito, Antonio Vaz Macedo, Heliz Regina Alves das Neves, Paula Moreira da Silva Sabaini, Monique Ammi, Flavia Ferreira da Costa, Adriana Mendes de Quadros Cavilha, Rosana Rocha Concilio, et al.

    The development of the Brazilian Registry of Hematopoietic Cell Transplantation (HCT) in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) continues to provide a comprehensive assessment of the activity and general outcomes of HCT in Brazil. In this paper, we report an update of such activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. The data then return to the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2024 from Brazilian centers were extracted from the CIBMTR. A descriptive analysis was carried out using patient, disease and transplant-specific variables and overall survival analysis using the Kaplan Meier method. A total of 14,331 patients were eligible for this study (6,583 autologous and 7,748 allogeneic HCTs). The number of reporting centers increased from 40 to 45 during the period. The most common HCT indication in Brazil for allogeneic HCT was AML, with 171 HCTs per year and, for autologous HCT, multiple myeloma, with 273 HCTs per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic HCTs, bone marrow (BM) was the most frequent among pediatric HCTs, while peripheral blood (PB) was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of HCTs. Patients with acute leukemia who underwent HCT at an advanced disease stage had lower survival rates compared to those at earlier stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (USA) Summary Slides.


  • Open Access

    Allogeneic Hematopoietic Cell Transplantation in Elderly Patients in a Latin American Country: Analysis of 11 Year of Data from the Brazilian Registry SBTMO/CIBMTR

    by Fernando Barroso Duarte, Yhasmine Delles Oliveira Garcia, Nelson Hamerschlak, Vaneuza Araújo Moreira Funke, Maria Claudia Rodrigues Moreira, Alessandra Aparecida Paz, Jayr Schmidt Filho, Claudia Caceres Astigarraga, Roberto Luiz da Silva, Vinícius Campos de Molla, et al.


  • Open Access

    CURRENT USE AND OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2024

    by Anderson João Simione, Cinthya Corrêa da Silva, Paula Moreira da Silva Sabaini, Antonio Vaz Macedo, Heliz Regina Alves das Neves, Bruna Letícia da Silva Santos Geraldo, Monique Ammi, Flavia Ferreira da Costa, Valeria Viana, Adriana Mendes de Quadros Cavilha, et al.

    The development of the Brazilian Registry of Hematopoietic Cell Transplantation in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) allowed for an assessment of the activity and general outcomes of transplants in Brazil. Here, we report an updated activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. Information returns to Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2023 from Brazilian centers were extracted from CIBMTR. Descriptive analysis was carried out by patient-, disease- and transplant-specific variables and overall survival analysis using Kaplan Meyer. A total of 12,230 patients were eligible for this study (5,573 autologous and 6,657 allogeneic transplants). The number of reporting centers increased from 40 to 44 during the period. The most common HCT indication in Brazil is AML for allogeneic HCT with 152 transplants year and multiple myeloma for autologous HCT with 245 transplants per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic transplants, BM was the most frequent among pediatric transplants, while PBSC was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of transplants. Patients with acute leukemia who underwent HCT with advanced stage disease had lower survival rates compared to those at other stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (US) Summary Slides.